Literature DB >> 28316215

[Effect of preoperative monocyte-lymphocyte ratio on prognosis of patients with resectable esophagogastric junction cancer].

W J Zhou1, J Wu1, X D Li1, Q Wang1, X F Ni1, J T Jiang1, M Ji1, C P Wu1.   

Abstract

Objective: To investigate the associations between various blood test parameters including MLR (monocyte-lymphocyte ratio) and prognosis in post-operative esophagogastric junction cancer patients.
Methods: We retrospectively studied the preoperative and postoperative data of 309 patients who underwent radical surgery for esophagogastric junction cancer. The relationship between MLR, neutrophil lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and overall survival (OS) was analyzed.
Results: The cutoff values of MLR、NLR and PLR were 0.201, 1.697 and 96.960, respectively. The median OS was 51.4 months for all the patients in the study group (n=309). MLR in patients with esophagogastric junction carcinoma was associated with gender, depth of invasion, histological grade, TNM stage, NLR and PLR (P<0.05). PLR was associated with tumor size, TNM stage, NLR and MLR (P<0.05). NLR was associated with gender, tumor size, TNM stage, PLR and MLR (both P<0.05). Univariate analysis showed that tumor size, depth of tumor invasion, metastasis of lymph nodes, pathological grading, nerve infiltration, lymphovascular invasion, TNM staging, PLR and MLR were associated with the median overall survival time (P<0.05). Multivariate analysis showed that TNM stage, nerve infiltration and MLR were independent prognostic predictors for patients with esophagogastric junction cancer (P<0.05), but not PLR or NLR. Setting the optimal cut-off value of the MLR in 0.201, the area under the curve was 0.603, significantly larger than that of PLR and NLR (P<0.05). Conclusions: Preoperative MLR is a very useful predictor of patients with esophagogastric junction cancer who underwent radical rescetion. Preoperative MLR> 0.201 is an independent risk factor for postoperative survival in patients with esophagogastric cancer, and PLR> 96.960 may predict a poor prognosis risk.

Entities:  

Keywords:  Curative resection; Esophagogastric junction cancer; Monocyte/lymphocyte ratio; Prognosis; Survival

Mesh:

Year:  2017        PMID: 28316215     DOI: 10.3760/cma.j.issn.0253-3766.2017.03.004

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  5 in total

1.  Development and Validation of a Nomogram for Predicting Overall Survival to Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Chenyu Wang; Xinyu Cheng; Linzhi Jin; Runchuan Ren; Shaohua Wang; Anping Zheng; Anlin Hao; Fuyou Zhou; Yaowen Zhang
Journal:  Biomed Res Int       Date:  2022-07-14       Impact factor: 3.246

Review 2.  Blood-based Markers in the Prognostic Prediction of Esophagogastric Junction Cancer.

Authors:  Can-Tong Liu; Chao-Qun Hong; Xu-Chun Huang; En-Min Li; Yi-Wei Xu; Yu-Hui Peng
Journal:  J Cancer       Date:  2020-04-27       Impact factor: 4.207

3.  Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis.

Authors:  Ruonan Yang; Qian Chang; Xianchun Meng; Nan Gao; Wanhai Wang
Journal:  J Cancer       Date:  2018-09-07       Impact factor: 4.207

4.  Preoperative Neutrophil Lymphocyte Ratio Can Be Used as a Predictor of Prognosis in Patients With Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta Analysis.

Authors:  Xiao-Bo Liu; Zi-Ye Gao; Qing-Hui Zhang; Sandeep Pandey; Bo Gao; Fan Yang; Qiang Tong; Sheng-Bao Li
Journal:  Front Oncol       Date:  2020-02-21       Impact factor: 6.244

5.  Prognostic value of the systemic inflammation response index in human malignancy: A meta-analysis.

Authors:  Lishuang Wei; Hailun Xie; Ping Yan
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.